Poolbeg Pharma PLC Announces Appointment of Joint Broker

Rhea-AI Summary

Poolbeg Pharma has appointed Singer Capital Markets as its Joint Broker, effective immediately. This addition complements existing collaborations with finnCap Ltd and J&E Davy. Poolbeg, a clinical-stage pharmaceutical company focused on infectious diseases, aims to advance multiple products efficiently. With a market expected to exceed $250 billion by 2025, Poolbeg utilizes insights from Open Orphan plc to enhance asset acquisition and clinical positioning, including several promising products in its pipeline.

Positive

• Appointment of Singer Capital Markets as Joint Broker may enhance market positioning.
• Access to experience and clinical data from Open Orphan plc supports faster product development.
• Targeting a rapidly growing infectious disease market expected to reach $250 billion by 2025.

Negative

• None.

LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd will continue to act as Nominated Adviser and Joint Broker alongside J&E Davy as additional Joint Broker.

- Ends -

Enquiries

Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO	+44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson Richard Chambers, Sunila de Silva (ECM), Nigel Birks	+44 (0) 207 220 0500
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher	+44 (0)20 7496 3000
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field	+44 (0) 20 7457 2020 poolbeg@instinctif.com

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to license or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) drug discovery programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected in Q4 2022.

For more information, please go to www.poolbegpharma.com or follow us on LinkedIn and Twitter @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Poolbeg Pharma PLC

View source version on accesswire.com:
https://www.accesswire.com/710223/Poolbeg-Pharma-PLC-Announces-Appointment-of-Joint-Broker

FAQ

What does the appointment of Singer Capital Markets as Joint Broker mean for Poolbeg Pharma (POLBF)?

The appointment of Singer Capital Markets is intended to strengthen Poolbeg Pharma's market positioning and support its growth strategy.

What are the expected benefits of Poolbeg Pharma's new broker partnership?

The partnership is expected to improve market access and provide additional advisory expertise during the company's growth phase.

How does Poolbeg Pharma plan to leverage its partnership with Open Orphan?

Poolbeg Pharma aims to use insights from Open Orphan to reduce development costs and risks while accelerating product acquisition.

What is the current focus of Poolbeg Pharma (POLBF) in the pharmaceutical market?

Poolbeg Pharma is focused on developing products for the growing infectious disease market, which is projected to become a major sector in pharmaceuticals.